Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma
10.3760/cma.j.cn371439-20230410-00106
- VernacularTitle:免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展
- Author:
Xinyi CHEN
1
;
Yiming WENG
;
Jiayan WEI
;
Jinsong WANG
;
Min PENG
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Head and neck neoplasms;
Carcinoma, squamous cell;
Therapy;
Immune checkpoint inhibitors
- From:
Journal of International Oncology
2023;50(9):553-557
- CountryChina
- Language:Chinese
-
Abstract:
With the increasing understanding of the complex interaction between the tumor microenvironment and immune therapy, the role of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (HNSCC) has gained significant attention. Immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) , cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) , and T cell immunoglobulin domain and mucin domain-3 (TIM-3) , such as pembrolizumab, durvalumab, tremelimumab, ipilimumab, and LY3321367, have been applied in numerous clinical trials as monotherapies and combination therapies for the treatment of recurrent or metastatic HNSCC. Further research into the efficacy and safety of these immune checkpoint inhibitors in clinical trials may provide more effective strategies for the treatment of patients with recurrent or metastatic HNSCC.
